{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Acer Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"ACER"},"Address":{"label":"Address","value":"300 WASHINGTON STREET ONE GATEWAY CENTER, SUITE 351, NEWTON, Massachusetts, 2458, United States"},"Phone":{"label":"Phone","value":"+1 844 902-6100"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.acertx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Adrian Quartel","title":"Chief Medical Officer"},{"name":"Christopher Schelling","title":"President, Chief Executive Officer &amp; Director"},{"name":"John M. Klopp","title":"Chief Technology Officer"},{"name":"Tanya Hayden","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}